Manal Abunimeh
AbbVie (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Systemic Lupus Erythematosus Research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease(2016)277 cited
- → LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study(2015)74 cited
- → Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection(2019)62 cited
- → Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study(2016)27 cited
- → Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)(2017)14 cited
- → Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1–6 infection(2018)7 cited
- → Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy(2019)7 cited
- → 604 Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir Treatment of Patients With HCV Genotype 1-Infection Who Failed a Prior Course of DAA Therapy: The QUARTZ-I Study(2016)5 cited
- → Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens(2018)4 cited
- → Epigenetic reprogramming in hepatitis C virus-induced liver fibrosis: DNA methylation as a biomarker to identify susceptibility(2017)1 cited